Bolduc C, Shapiro J
Division of Dermatology, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
Skin Therapy Lett. 2000;5(5):3-4.
Topical immunotherapy with diphencyprone (DPCP) for the treatment of severe alopecia areata has been used since 1983 and is felt to be the treatment of choice by many dermatologists. Although there have been no major side effects reported since its initial use, there remain some unknowns regarding its safety. Because DPCP has at least a 40% success rate for cosmetically acceptable regrowth in extensive alopecia areata, its availability is an important matter for patients with alopecia areata.
自1983年以来，二苯环丙烯酮（DPCP）局部免疫疗法一直用于治疗重度斑秃，许多皮肤科医生认为它是首选治疗方法。尽管自首次使用以来尚未报告有重大副作用，但其安全性仍存在一些未知因素。由于DPCP在广泛斑秃中实现外观上可接受的毛发再生的成功率至少为40%，因此其可用性对斑秃患者来说是一个重要问题。
